Estrogen Dosing for Transgender Women
I cannot provide a definitive recommendation for transgender feminizing hormone therapy based on the evidence provided, as all the guideline evidence addresses premature ovarian insufficiency (POI) in cisgender women—a completely different clinical context with different physiologic goals, safety considerations, and dosing requirements.
Critical Evidence Gap
The provided guidelines 1, 2, 1, 2, 1 exclusively address hormone replacement in adolescents and young women with chemotherapy- or radiation-induced POI. These recommendations aim to replace deficient endogenous hormones to achieve physiologic female levels in individuals with ovarian failure. This is fundamentally different from transgender feminizing therapy, which aims to suppress endogenous testosterone and induce feminization in individuals with functioning testes.
What the Research Evidence Shows
The most recent research studies 3, 4, 5, 6, 7, 8, 9 consistently demonstrate that:
Current guideline-recommended injectable estradiol doses (5-30 mg every 2 weeks or 2-10 mg weekly) are too high and frequently produce supraphysiologic estradiol levels 3, 4
Injectable estradiol should be started at ≤5 mg weekly (subcutaneous or intramuscular) to avoid excessive levels 4
Even lower doses (3-4 mg weekly) of estradiol valerate achieve target levels in 76-78% of patients 5
Intramuscular/subcutaneous estradiol is more potent than oral or transdermal routes for testosterone suppression 7, 8
The guideline-recommended target range of 100-200 pg/mL lacks evidence for optimal feminization outcomes 9
Practical Approach Based on Research Evidence
Starting Doses by Route:
Injectable estradiol (valerate or cypionate):
- Start at 3-5 mg weekly subcutaneously or intramuscularly 4, 5
- Doses above 5 mg weekly frequently cause supraphysiologic levels 3, 4, 6
Oral estradiol:
- Demonstrates linear dose-response for testosterone suppression 7
- Each 1 mg/day increase reduces testosterone by approximately 19 ng/dL 7
Transdermal estradiol:
- Guideline-concordant doses frequently produce subtherapeutic levels 6
- May require higher doses than traditionally recommended
Monitoring and Titration:
- Check estradiol levels mid-cycle for injectable formulations 4, 5
- Titrate based on testosterone suppression and feminization progress, not solely estradiol levels 9
- Target testosterone <50 ng/dL is achievable in 84-90% of patients with appropriate dosing 5
Common Pitfalls
Do not use POI dosing guidelines for transgender care—the 50-100 μg transdermal patches recommended for POI 1 are designed for hormone replacement, not gender-affirming therapy.
Avoid starting injectable estradiol at doses >5 mg weekly—this consistently produces excessive estradiol levels across multiple recent studies 3, 4, 5, 6.
Do not rely solely on the 100-200 pg/mL target range—this lacks validation for transgender patients and may not correlate with optimal feminization 9.